Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130228113736im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.
Condition | Intervention |
---|---|
Lymphoma Nonneoplastic Condition |
Genetic: DNA analysis Genetic: RNA analysis Other: laboratory biomarker analysis |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Prospective |
Official Title: | Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073) |
- Change in viral load from baseline to each subsequent time point [ Time Frame: Baseline, after each cycle of treatment, restaging, treatment completion, year 1, year 2, study discontinuation ] [ Designated as safety issue: No ]Time frame for outcome measures dependent on study calendar for parent protocol, S0816, which varies by subject's PET scan status.
Biospecimen Retention: Samples With DNA
PBMC
Enrollment: | 1 |
Study Start Date: | June 2011 |
Study Completion Date: | January 2013 |
Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- To quantify HIV-1 persistence in prospectively collected samples from patients on suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma.
OUTLINE: This is a multicenter study.
Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood mononuclear cells).
After completion of treatment, patients are followed up periodically for up to 2 years.
![](https://webarchive.library.unt.edu/web/20130228113736im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Clinical trial participants (subjects who are participating in parent protocol S0816 and provide informed consent for participation in this substudy).
DISEASE CHARACTERISTICS:
HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry
- Documentation may be serologic (positive ELISA and positive western blot), or other federally approved licensed HIV diagnostic test
- Prior documentation of HIV seropositivity is acceptable
- Diagnosis of untreated Hodgkin lymphoma and participation in the parent protocol SWOG-S0816, "A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging."
PATIENT CHARACTERISTICS:
- No psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator
- Willing to provide serial blood samples
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
![](https://webarchive.library.unt.edu/web/20130228113736im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Baltimore, Maryland, United States, 21231-2410 |
Principal Investigator: | John W. Mellors, MD | University of Pittsburgh |
![](https://webarchive.library.unt.edu/web/20130228113736im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | AIDS Malignancy Clinical Trials Consortium |
ClinicalTrials.gov Identifier: | NCT01319526 History of Changes |
Other Study ID Numbers: | CDR0000690149, AMC-079 |
Study First Received: | December 18, 2010 |
Last Updated: | January 7, 2013 |
Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by AIDS Malignancy Clinical Trials Consortium:
stage III adult Hodgkin lymphoma stage IV adult Hodgkin lymphoma HIV infection |
Additional relevant MeSH terms:
HIV Infections Hodgkin Disease Lymphoma Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
ClinicalTrials.gov processed this record on February 26, 2013